December 12, 2022

SABCS Reactions - DESTINY-Breast02

December 12, 2022

SABCS Reactions - DESTINY-Breast02

Author

Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02.

Abstract #GS2-01: Ian [DKM1] Krop presented primary results of the P3 DESTINY-Breast02 trial (a confirmatory study for the pivotal P2 DESTINY-Breast01 trial), assessing trastuzumab deruxtecan (T-DXd)vs physician’s choice (TPC) in 608 patients withHER2+ mBC previously treated with trastuzumab emtansine.

Results:

  • T-DXd significantly improved median PFS vs TPC (as measured by BICR: 17.8 vs. 6.9 months; as measured by investigator: 16.7 vs. 5.5 months)
  • T-DXd significantly improved median OS vs TPC (39.2 vs 26.5 months)
  • Confirmed ORR T-DXd vs TPC was 69.7% (14% CR) vs. 29.2% (5.0% CR)
  • Overall safety profile consistent with established safety for T-DXd
  • Grade ≥3 TEAEs occurred in 52.7% vs. 44.1% for T-DXd vs. TPC
  • Adjudicated drug-related interstitial lung disease (ILD) occurred in 10.4% vs. 0.5% of pts with T-DXd vs TPC; fewer grade 5 ILD than DESTINY-Breast 01
  • Discontinuations in 19.8% of cases in T-DXd vs 9.7% of cases in TPC
  • SABCS Reactions - DESTINY-Breast02

    Thought leader reactions were positive, with several oncologists lauding the clinically significant improvement in PFS and OS

    saroj
    Hope
    Stephaine
    Jame

    Rates of interstitial lung disease, while less prevalent than in the DESTINY-Breast01 trial, are still a cause for concern

    Angela
    Mridula
    Amol

    One thought leader raised the need for predictive biomarkers for interstitial lung disease:

    Lorenzo

    Summary:

    Despite lingering concerns regarding interstitial lung disease, thought leaders believe that T-DXd has an important place in the treatment of HER2+ mBC previously treated with T-DM1.

    Opus
    Synthesis provided by Opus Strategy LLC.
    Download attached file
    Not rated
    Allison Betof Warner, MD, PhD (she/her) 4
    3743
    Manhattan, NY
    November 10, 2022

    79% had reduction in disease. ORR 31%. Many responses deepen over time.

    Not rated
    Allison Betof Warner, MD, PhD (she/her) 3
    3743
    Manhattan, NY
    November 10, 2022

    Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

    Positive
    Alex Shoushtari, MD
    2253
    New York, USA
    November 10, 2022

    Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

    Not rated
    Allison Betof Warner, MD, PhD (she/her) 2
    3743
    Manhattan, NY
    November 10, 2022

    Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

    Positive
    Hussein Tawbi, MD, PhD
    1685
    Houston, TX
    November 10, 2022

    Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

    Positive
    Allison Betof Warner, MD, PhD (she/her) 1
    3744
    Manhattan, NY
    November 10, 2022

    Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

    Not Rated
    Sumanta K. Pal, MD, FASCO
    15083 Followers
    Los Angeles, CA
    November 8, 2022

    Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

    not rated
    Shilpa Gupta
    5095 Followers
    Cleveland, OH
    November 8, 2022
    Not Rated
    Tian Zhang, MD, MHS
    6463 Followers
    Dallas, TX
    November 8, 2022

    CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

    Not Rated
    Moshe Ornstein MD
    1930 Followers
    Cleveland, OH
    November 8, 2022

    Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

    Not Rated
    Shuchi Gulati MD
    12476 Followers
    Seattle, WA
    November 8, 2022

    Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

    Not Rated
    Petros Grivas
    12476 Followers
    Seattle, WA
    November 8, 2022

    Subscribe to our newsletter

    Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
    Thank you! Your submission has been received!
    Oops! Something went wrong while submitting the form.